Comparison of lisdexamfetamine and dextroamphetamine exposures reported to U.S. poison centers

Clinical Toxicology

Volumn 53, Issue 5, 2015, Pages 477-485

  Kaland, Mingzohn Ellen ^a   Klein Schwartz, Wendy ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Abuse; ADHD; Overdose; Toxicity

Indexed keywords

AMPHETAMINE PLUS DEXAMPHETAMINE; DEXAMPHETAMINE; LISDEXAMFETAMINE; CENTRAL STIMULANT AGENT; DELAYED RELEASE FORMULATION;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGITATION; ARTICLE; BRADYCARDIA; BRAIN HEMORRHAGE; CASE STUDY; CHILD; DEMOGRAPHY; DRUG ABUSE; DRUG MISUSE; FEMALE; HEART ARREST; HEART ARRHYTHMIA; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPERTENSION; HYPOTENSION; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; POISON CENTER; RESPIRATION DEPRESSION; RESPIRATORY ARREST; RETROSPECTIVE STUDY; SEIZURE; SUICIDE ATTEMPT; TACHYCARDIA; THERAPEUTIC ERROR; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DRUG OVERDOSE; INTOXICATION; MEDICATION ERROR; MORTALITY; RISK; RISK FACTOR; STATISTICAL MODEL; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AMPHETAMINE-RELATED DISORDERS; CENTRAL NERVOUS SYSTEM STIMULANTS; CHI-SQUARE DISTRIBUTION; CHILD; DELAYED-ACTION PREPARATIONS; DEXTROAMPHETAMINE; DRUG OVERDOSE; HUMANS; LINEAR MODELS; MEDICATION ERRORS; ODDS RATIO; POISON CONTROL CENTERS; POISONING; RETROSPECTIVE STUDIES; RISK FACTORS; SUICIDE, ATTEMPTED; UNITED STATES; YOUNG ADULT;

EID: 84929076147     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.3109/15563650.2015.1027903     Document Type: Article

References (25)

1. Steer C, Froelich J, Soutullo CA, Johnson M, Shaw M. Lisdexamfetamine dimesylate: A new therapeutic option for attention-deficit hyperactivity disorder. CNS Drugs 2012; 26:691-705.
2. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 1998; 94:127-152.
3. Jasinski R, Krishnan S. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol 2009; 23:410-418.
4. LoVecchio F, Ozimek J, Sawyers B, Thole D. Outcomes after accidental pediatric ingestions of (dextro)amphetamine and methylphenidate. Am J Emerg Med 2009; 27:933-934.
5. Findling RL, Ginsberg LD, Jain R, Gao J. Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attentiondeficit/ hyperactivity disorder: An open-label, dose-optimization study. J Child Adolesc Psychopharmacol 2009; 19:649-662.
6. Findling RL, Childress AC, Cutler AJ, Gasior M, Hamdani M, Ferreira-Cornwell MC, Squires L. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2011; 50:395-405.
7. Mowry JB, Spyker DA, Cantilena LR, Bailey JE, Ford M. 2012 Annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 30th Annual Report. Clin Toxicol 2013; 51:949-1229.
8. Gaynes BN, Christian R, Saavedra LM, Wines R, Janas DE, Viswanathan M, et al. Attention-deficit/hyperactivity disorder: Identifying high priority future research needs. J Psychiatric Pract 2014; 20:104-117.
9. Bloom B, Jones LI, Freeman G. Summary health statistics for U.S. children: National Health Interview Survey, 2012. Vital Health Stat 10 2013; (258):1-81.
10. U.S. Drug Enforcement Administration. Office of Diversion Control. National Forensic Laboratory Information System (NFLIS). (November 2012). Special Report: ADD/ADHD stimulants in NFLIS, 2007-2011. Springfield, VA.
11. Torsoli A. Shire falls most since June on Adderall XR competition. BloombergBusiness. February 14, 2013. Available at: http://www. bloomberg.com/news/articles/2013-02-14/shire-profit-beats-estimates-amid-adderall-xr-sales-drop. Accessed 2/6/2015.
12. Spiller HA, Hays HL, Aleguas A. Overdose of drugs for attentiondeficit hyperactivity disorder: Clinical presentation, mechanisms of toxicity and management. CNS Drugs 2013; 27:531-543.
13. Krishnan S, Montcrief S. Toxicity profile of lisdexamfetamine dimesylate in three independent rat toxicology studies. Basic Clin Pharmacol Toxicol 2007; 101:231-240.
14. Coghill DR, Caballero B, Sorooshian S, Civil R. A systematic review of the safety of lisdexamfetamine dimesylate. CNS Drugs 2014; 28:497-511.
15. Spiller HA, Griffith JRK, Anderson DL, Weber JA. Poison centers detect an unexpectedly frequent number of adverse reactions to lisdexamfetamine. Ann Pharmacother 2008; 42:1142-1143.
16. Chundru PG, Morgan DL, Borys DJ. Clinical effects and outcomes following unintentional double dose of lisdexamfetamine (Vyvanse) in pediatrics. Clin Toxicol 2010; 48:654. (abstract)
17. Akingbola OA, Singh D. Dexmedetomidine to treat lisdexamfetamine overdose and serotonin toxidrome in a 6-year-old girl. Am J Crit Care 2012; 21:456-459.
18. Meggs WJ, Cowan LR, Schmidt J, Riordilisi I, Rodriguez L. Benzodiazepine resistant sympathomimetic toxidrome responding to pentobarbital. Clin Toxicol 2010; 48:248. (abstract)
19. Spaziani ML, Schult RF, Wiegand TJ. Lisdexamfetamine ingestion resulting in hypertensive emergency treated with phentolamine. Clin Toxicol 2014; 52:406. (abstract)
20. Burgard DA, Fuller R, Becker B, Ferrell R, Dinglasan-Panlilio MJ. Potential trends in attention deficit hyperactivity disorder (ADHD) drug use on a college campus: wastewater analysis of amphetamine and ritalinic acid. Sci Total Environ 2013; 450-451: 242-249.
21. Cassidy TA, McNaughton EC, Varughese S, Russo L, Budman SH, Eaton TA, Butler SFB. Nonmedical use and diversion of ADHD stimulants among U.S. adults ages 18-49: a national internet survey. J Atten Disord 2012 Dec 26 [Epub ahead of print].
22. Varughese S, Rosen S, Ertischek MD, Sembower MA, St. Jean E, Schnoll SH. Nonmedical use surveillance and signal identification of lisdexamfetamine dimesylate, a prodrug stimulant to treat ADHD. Am J Addict 2011; 20:373-374.
23. Krishnan SM, Pennick M, Stark JG. Metabolism, distribution and elimination of lisdexamfetamine dimesylate. Open-Label, single-centre, Phase I study in healthy adult volunteers. Clin Drug Invest 2008; 28:745-755.
24. Hoffman RS. Understanding the limitations of retrospective analyses of poison center data. Clin Toxicol 2007; 45:943-945.
25. Jaramillo JE, Marchbanks B, Willis B, Forrester MB. Evaluation of completeness of selected poison center data fields. J Med Syst 2010; 34:499-507.